<VariationArchive VariationID="1076185" VariationName="NM_001110792.2(MECP2):c.231del (p.Glu78fs)" VariationType="Deletion" Accession="VCV001076185" Version="7" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-03-05" DateCreated="2021-05-10" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1065224" VariationID="1076185">
      <GeneList>
        <Gene Symbol="MECP2" FullName="methyl-CpG binding protein 2" GeneID="4204" HGNC_ID="HGNC:6990" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154021573" stop="154097717" display_start="154021573" display_stop="154097717" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153287263" stop="153363187" display_start="153287263" display_stop="153363187" Strand="-" />
          </Location>
          <OMIM>300005</OMIM>
          <Haploinsufficiency last_evaluated="2021-02-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MECP2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-02-22" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MECP2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_001110792.2(MECP2):c.231del (p.Glu78fs)</Name>
      <CanonicalSPDI>NC_000023.11:154032388:T:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="154032389" stop="154032389" display_start="154032389" display_stop="154032389" variantLength="1" positionVCF="154032388" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="153297840" stop="153297840" display_start="153297840" display_stop="153297840" variantLength="1" positionVCF="153297839" referenceAlleleVCF="CT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>E66fs</ProteinChange>
      <ProteinChange>E78fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.153297840del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.153297840del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.154032389del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.154032389del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007107.3" sequenceAccession="NG_007107" sequenceVersion="3" change="g.109715del">
            <Expression>NG_007107.3:g.109715del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001110792.2" sequenceAccession="NM_001110792" sequenceVersion="2" change="c.231del" MANESelect="true">
            <Expression>NM_001110792.2:c.231del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001104262.1" sequenceAccession="NP_001104262" sequenceVersion="1" change="p.Glu78fs">
            <Expression>NP_001104262.1:p.Glu78fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001316337.2" sequenceAccession="NM_001316337" sequenceVersion="2" change="c.-85del">
            <Expression>NM_001316337.2:c.-85del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001369391.2" sequenceAccession="NM_001369391" sequenceVersion="2" change="c.-85del">
            <Expression>NM_001369391.2:c.-85del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001369392.2" sequenceAccession="NM_001369392" sequenceVersion="2" change="c.-85del">
            <Expression>NM_001369392.2:c.-85del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001369393.2" sequenceAccession="NM_001369393" sequenceVersion="2" change="c.-85del">
            <Expression>NM_001369393.2:c.-85del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001369394.2" sequenceAccession="NM_001369394" sequenceVersion="2" change="c.-85del">
            <Expression>NM_001369394.2:c.-85del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001386137.1" sequenceAccession="NM_001386137" sequenceVersion="1" change="c.-366del">
            <Expression>NM_001386137.1:c.-366del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001386138.1" sequenceAccession="NM_001386138" sequenceVersion="1" change="c.-366del">
            <Expression>NM_001386138.1:c.-366del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001386139.1" sequenceAccession="NM_001386139" sequenceVersion="1" change="c.-366del">
            <Expression>NM_001386139.1:c.-366del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004992.4" sequenceAccession="NM_004992" sequenceVersion="4" change="c.195del" MANEPlusClinical="true">
            <Expression>NM_004992.4:c.195del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004983.1" sequenceAccession="NP_004983" sequenceVersion="1" change="p.Glu66fs">
            <Expression>NP_004983.1:p.Glu66fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_764" sequenceAccession="LRG_764">
            <Expression>LRG_764:g.109715del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_764t1" sequenceAccession="LRG_764t1">
            <Expression>LRG_764t1:c.231del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_764p1" sequenceAccession="LRG_764p1" change="p.Glu78fs">
            <Expression>LRG_764p1:p.Glu78fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_764t2" sequenceAccession="LRG_764t2">
            <Expression>LRG_764t2:c.195del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_764p2" sequenceAccession="LRG_764p2" change="p.Glu66fs">
            <Expression>LRG_764p2:p.Glu66fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2148666876" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001110792.2(MECP2):c.231del (p.Glu78fs) AND Severe neonatal-onset encephalopathy with microcephaly" Accession="RCV001390003" Version="6">
        <ClassifiedConditionList TraitSetID="6528">
          <ClassifiedCondition DB="MedGen" ID="C1968556">Severe neonatal-onset encephalopathy with microcephaly</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-03-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-03-15" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-05-10" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10577905</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11058114</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23270700</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24283265</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24511209</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6528" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1150" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Encephalopathy, neonatal severe</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Severe neonatal-onset encephalopathy with microcephaly</ElementValue>
                <XRef ID="MONDO:0010397" DB="MONDO" />
                <XRef ID="209370" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Encephalopathy, neonatal severe, due to MECP2 mutations</ElementValue>
                <XRef ID="Encephalopathy%2C+neonatal+severe%2C+due+to+MECP2+mutations/8310" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17103" />
                <XRef ID="17103" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of MECP2-related phenotypes in females ranges from classic Rett syndrome to variant Rett syndrome with a broader clinical phenotype (either milder or more severe than classic Rett syndrome) to mild learning disabilities; the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability. Females: Classic Rett syndrome, a progressive neurodevelopmental disorder primarily affecting girls, is characterized by apparently normal psychomotor development during the first six to 18 months of life, followed by a short period of developmental stagnation, then rapid regression in language and motor skills, followed by long-term stability. During the phase of rapid regression, repetitive, stereotypic hand movements replace purposeful hand use. Additional findings include fits of screaming and inconsolable crying, autistic features, panic-like attacks, bruxism, episodic apnea and/or hyperpnea, gait ataxia and apraxia, tremors, seizures, and acquired microcephaly. Males: Severe neonatal-onset encephalopathy, the most common phenotype in affected males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years.</Attribute>
                <XRef ID="NBK1497" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MECP2-Related Severe Neonatal Encephalopathy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MECP2-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="Genetics Home Reference (GHR) links">MECP2-related severe neonatal encephalopathy</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301670</ID>
                <ID Source="BookShelf">NBK1497</ID>
              </Citation>
              <XRef ID="209370" DB="Orphanet" />
              <XRef ID="C1968556" DB="MedGen" />
              <XRef ID="MONDO:0010397" DB="MONDO" />
              <XRef Type="MIM" ID="300673" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3117250" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="10222596|MedGen:C1968556" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001591571" DateUpdated="2024-02-28" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-03-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10577905</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23270700</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24511209</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11058114</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24283265</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the MECP2 protein. Other variant(s) that disrupt this region (p.Arg168*) have been determined to be pathogenic (PMID: 10577905, 23270700, 24511209, 11058114, 24283265). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with MECP2-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the MECP2 gene (p.Glu66Lysfs*59). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 421 amino acids of the MECP2 protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MECP2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.153297840del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1968556" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3117250" TraitType="Disease" MappingType="XRef" MappingValue="C1968556" MappingRef="MedGen">
        <MedGen CUI="C1968556" Name="Severe neonatal-onset encephalopathy with microcephaly" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

